CX3CL1 Pathway as a Molecular Target for Treatment Strategies in Alzheimer’s Disease

CX3CL1 Pathway as a Molecular Target for Treatment Strategies in Alzheimer’s Disease

Alzheimer’s disease (AD) is a scourge for patients, caregivers and healthcare professionals due to the progressive character of the disease and the lack of effective treatments. AD is considered a proteinopathy, which means that aetiological and clinical features of AD have been linked to the deposi...

Full description

Bibliographic Details
Main Authors:	Giulia Bivona, Matilda Iemmolo, Giulio Ghersi
Format:	Article
Language:	English
Published:	MDPI AG 2023-05-01
Series:	International Journal of Molecular Sciences
Subjects:	Alzheimer’s disease pathogenesis microglia CX3CL1 neuron-to-glia communication fractalkine
Online Access:	https://www.mdpi.com/1422-0067/24/9/8230

Similar Items

The Cytokine CX3CL1 and ADAMs/MMPs in Concerted Cross-Talk Influencing Neurodegenerative Diseases
by: Matilda Iemmolo, et al.
Published: (2023-04-01)

Two forms of CX3CL1 display differential activity and rescue cognitive deficits in CX3CL1 knockout mice
by: Aimee N. Winter, et al.
Published: (2020-05-01)

High Cerebrospinal Fluid CX3CL1 Levels in Alzheimer’s Disease Patients but Not in Non-Alzheimer’s Disease Dementia
by: Giulia Bivona, et al.
Published: (2022-09-01)

Fractalkine/CX3CL1 in Neoplastic Processes
by: Jan Korbecki, et al.
Published: (2020-05-01)

Interaction of Tau with the chemokine receptor, CX3CR1 and its effect on microglial activation, migration and proliferation
by: Hariharakrishnan Chidambaram, et al.
Published: (2020-09-01)

The role of the CX3CL1/CX3CR1 axis as potential inflammatory biomarkers in subjects with periodontitis and rheumatoid arthritis: A systematic review
by: Mario A. Alarcón‐Sánchez, et al.
Published: (2024-02-01)

Effects of Cerebrospinal Fluids from Alzheimer and Non-Alzheimer Patients on Neurons–Astrocytes–Microglia Co-Culture
by: Matilda Iemmolo, et al.
Published: (2024-02-01)

The chemokine fractalkine (CX3CL1) attenuates H2O2-induced demyelination in cerebellar slices
by: Sinead A. O’Sullivan, et al.
Published: (2017-08-01)

Decreased CX3CL1 Levels in the Cerebrospinal Fluid of Patients With Alzheimer’s Disease
by: Juan R. Perea, et al.
Published: (2018-09-01)

Fractalkine (CX3CL1) and Its Receptor CX3CR1: A Promising Therapeutic Target in Chronic Kidney Disease?
by: Sarah Cormican, et al.
Published: (2021-06-01)

Bone Marrow CX3CL1/Fractalkine is a New Player of the Pro-Angiogenic Microenvironment in Multiple Myeloma Patients
by: Valentina Marchica, et al.
Published: (2019-03-01)

Tenophages: a novel macrophage-like tendon cell population expressing CX3CL1 and CX3CR1
by: Christine Lehner, et al.
Published: (2019-12-01)

Modulating neurotoxicity through CX3CL1/CX3CR1 signaling
by: Cristina eLimatola, et al.
Published: (2014-08-01)

Neuron–glia crosstalk in health and disease: fractalkine and CX3CR1 take centre stage
by: Graham K. Sheridan, et al.
Published: (2013-01-01)

Heterozygous CX3CR1 Deficiency in Microglia Restores Neuronal β-Amyloid Clearance Pathways and Slows Progression of Alzheimer's Like-Disease in PS1-APP Mice
by: Suzanne E. Hickman, et al.
Published: (2019-12-01)

The Impact of the CX3CL1/CX3CR1 Axis in Neurological Disorders
by: Paulina Pawelec, et al.
Published: (2020-10-01)

Fractalkine/CX3CR1 Pathway in Neuropathic Pain: An Update
by: Rita Silva, et al.
Published: (2021-07-01)

Defective microglial development in the hippocampus of Cx3cr1 deficient mice
by: Francesca ePagani, et al.
Published: (2015-03-01)

Pathophysiological impact of CXC and CX3CL1 chemokines in preeclampsia and gestational diabetes mellitus
by: Amin Ullah, et al.
Published: (2023-10-01)

CX<sub>3</sub>CL1 (fractalkine) and CX<sub>3</sub>CR1 expression in myelin oligodendrocyte glycoprotein-induced experimental autoimmune encephalomyelitis: kinetics and cellular origin
by: Olsson Tomas, et al.
Published: (2005-07-01)

CX3CL1 Action on Microglia Protects from Diet-Induced Obesity by Restoring POMC Neuronal Excitability and Melanocortin System Activity Impaired by High-Fat Diet Feeding
by: Jineta Banerjee, et al.
Published: (2022-06-01)

Berberine Suppresses Leukocyte Adherence by Downregulating CX3CL1 Expression and Shedding and ADAM10 in Lipopolysaccharide-Stimulated Vascular Endothelial Cells
by: Yi-Hong Wu, et al.
Published: (2022-04-01)

FRACTALKINE: PATHOGENIC ROLE AND DIAGNOSTIC CAPABILITIES
by: O. A. MESNYANKINA, et al.
Published: (2017-06-01)

Treatment with an Anti-CX3CL1 Antibody Suppresses M1 Macrophage Infiltration in Interstitial Lung Disease in SKG Mice
by: Satoshi Mizutani, et al.
Published: (2021-05-01)

CX3CL1(+) Microparticles Mediate the Chemoattraction of Alveolar Macrophages toward Apoptotic Acute Promyelocytic Leukemic Cells
by: Wen-Hui Tsai, et al.
Published: (2014-02-01)

MicroRNA-424 regulates the expression of CX3CL1 (fractalkine) in human microvascular endothelial cells during Rickettsia rickettsii infection
by: Abha Sahni, et al.
Published: (2021-03-01)

Potential significance of CX3CR1 dynamics in stress resilience against neuronal disorders
by: Koichi Inoue
Published: (2022-01-01)

CX3CL1/CX3CR1 axis attenuates early brain injury via promoting the delivery of exosomal microRNA-124 from neuron to microglia after subarachnoid hemorrhage
by: Xiao Chen, et al.
Published: (2020-07-01)

Fractalkine Is Linked to the Necrosome Pathway in Acute Pulmonary Inflammation
by: Kristian-Christos Ngamsri, et al.
Published: (2021-03-01)

Research advances of chemokine receptor CX3CR1 and microglia in retinal degenerative diseases
by: Yu-Lin Qi, et al.
Published: (2021-08-01)

Role of fractalkine–CX3CR1 pathway in seizure-induced microglial activation, neurodegeneration, and neuroblast production in the adult rat brain
by: Idrish Ali, et al.
Published: (2015-02-01)

Fractalkine Signalling (CX<sub>3</sub>CL1/CX<sub>3</sub>CR1 Axis) as an Emerging Target in Coronary Artery Disease
by: Shu Xian Loh, et al.
Published: (2023-07-01)

Fractalkine/CX<sub>3</sub>CR1 in Dilated Cardiomyopathy: A Potential Future Target for Immunomodulatory Therapy?
by: Visvesh Jeyalan, et al.
Published: (2023-09-01)

Chemokine Fractalkine and Non-Obstructive Coronary Artery Disease—Is There a Link?
by: Aleksandra Stangret, et al.
Published: (2024-03-01)

CX3CL1/CX3CR1 signal mediates M1-type microglia and accelerates high-altitude-induced forgetting
by: Xueting Wang, et al.
Published: (2023-05-01)

Platelets are recruited to hepatocellular carcinoma tissues in a CX3CL1‐CX3CR1 dependent manner and induce tumour cell apoptosis
by: Shuo Miao, et al.
Published: (2020-10-01)

Identifying a Novel Role for Fractalkine (CX3CL1) in Memory CD8+ T Cell Accumulation in the Omentum of Obesity-Associated Cancer Patients
by: Melissa J. Conroy, et al.
Published: (2018-08-01)

Reduced brain fractalkine-CX3CR1 signaling is involved in the impaired cognition of streptozotocin-treated mice
by: Namiko Kawamura, et al.
Published: (2020-12-01)

The Impact of Uremic Toxicity Induced Inflammatory Response on the Cardiovascular Burden in Chronic Kidney Disease
by: Ligia Maria Claro, et al.
Published: (2018-09-01)

CX3CL1 promotes MMP-3 production via the CX3CR1, c-Raf, MEK, ERK, and NF-κB signaling pathway in osteoarthritis synovial fibroblasts
by: Sheng-Mou Hou, et al.
Published: (2017-12-01)